Published in Biotech Law Weekly, November 11th, 2005
According to investigators in the Netherlands, "Many studies have shown differences between statins based on surrogate endpoints, but few have studied differences in reaching clinical endpoints. [Our] study compares the risk of cardiovascular and cerebrovascular events between atorvastatin users and other statin users in daily general practice."
J.P. Dieleman and colleagues of Erasmus University in Rotterdam explained, "A cohort study was performed in the Integrated Primary Care Information project database, a longitudinal general practice research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.